共 50 条
PTCL, NOS: An update on classification, risk-stratification, and treatment
被引:11
|作者:
Weiss, Jonathan
[1
]
Reneau, John
[2
]
Wilcox, Ryan A. A.
[1
]
机构:
[1] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA
[2] Ohio State Univ, Dept Med, Div Hematol, Comprehens Canc Ctr, Columbus, OH USA
来源:
关键词:
PTCL-NOS;
PTCL;
GATA-3;
risk stratification;
classification;
treatment;
PERIPHERAL T-CELL;
TRANSCRIPTION FACTOR GATA-3;
NON-HODGKIN-LYMPHOMA;
HEALTH-ORGANIZATION CLASSIFICATION;
PIVOTAL PHASE-II;
OPEN-LABEL;
SINGLE-AGENT;
ACTIVATING MUTATIONS;
BRENTUXIMAB VEDOTIN;
POOR-PROGNOSIS;
D O I:
10.3389/fonc.2023.1101441
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
The peripheral T-cell lymphomas (PTCL) are relatively rare, heterogeneous, and therapeutically challenging. While significant therapeutic gains and improved understanding of disease pathogenesis have been realized for selected PTCL subtypes, the most common PTCL in North America remains "not otherwise specified (NOS)" and is an unmet need. However, improved understanding of the genetic landscape and ontogeny for the PTCL subtypes currently classified as PTCL, NOS have been realized, and have significant therapeutic implications, which will be reviewed here.
引用
收藏
页数:12
相关论文